The Therapeutic Goods Administration (TGA) has updated the list of ingredients permitted for use in listed medicines through the Therapeutic Goods (Permissible Ingredients) Determination (No. 1) 2026, which came into force on 1 March 2026. The new instrument replaces the previous Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2025 and introduces revisions to ingredient requirements and permitted uses.

Under the updated determination, 22 ingredients have been amended, reflecting updates to regulatory conditions governing their use in listed medicines. The revised substances include Polyisobutylene, Stannic oxide, Calcium hydroxycitrate, Hydroxycitric acid, Hydroxycitrate complex, Potassium hydroxycitrate, Sodium hydroxycitrate, Phenoxyethanol, Sorbitan distearate, Stearoyl glutamic acid, and botanical ingredients such as Garcinia gummi-gutta, Garcinia quaesita, Parsley herb derivatives (dry, oil, powder), Parsley seed oil, Petroselinum crispum, Rue oil, Ruta graveolens, Xanthium sibiricum, and Xanthium strumarium. Additional amendments include Lauryl methacrylate/sodium methacrylate crosspolymer dispersion (40%).

The determination forms part of Australia’s regulatory framework for listed medicines, ensuring that ingredients used in these products meet current safety and quality requirements. As the instrument is regularly updated, stakeholders are advised to consult the latest version available through the official Therapeutic Goods Determination portal to ensure ongoing compliance.

Consumer News Tags
Australia, Therapeutic Goods Administration, TGA, permissible ingredients list